Where to start: How to gain a foothold in the China biopharmaceutical market

May 9, 2017 Erin Righetti

The China pharmaceutical market has come of age. With record breaking investments in innovative companies, support from the CFDA, and new product approvals pending, China has entered a new age as a global competitor in new drug development and commercialization. China remains the second largest global economy, with USD 5.3 billion+ in VC investment in the life sciences sector in 2016. There are more market entry opportunities than ever before.

ChinaBio® Group, a leading consulting and advisory partner with significant experience in China’s life science industry, has put together an insider’s list of the Top 100* pharmaceutical companies in China to make it easier for life science BD teams to scout and pursue successful cross-partnerships with China-based companies.

Download the “Top 100 pharmaceutical companies in China” list now.

To meet and partner with over 900 global executives from pharma, biotech, finance and cross-border partners, register to attend ChinaBio® Partnering Forum taking place in Zhuhai, China, May 31–June 1, 2017.

*ranking based on revenue, recognition factor, partnering ability, and other criteria selected by ChinaBio® Group

 

 

About the Author

Erin Righetti

Editor-in-Chief, Insight

Follow on Twitter More Content by Erin Righetti
Previous Article
The Advocate of Rare Disease Advocates: Remembering Henri Termeer
The Advocate of Rare Disease Advocates: Remembering Henri Termeer

We were saddened to come to work Monday morning to discover that innovator, industry giant and Genzyme foun...

Next Article
Health tech innovators pitch business ideas to expert panel at BIO-Europe Spring®
Health tech innovators pitch business ideas to expert panel at BIO-Europe Spring®

The buzz steadily grew as the Health Tech Competition got underway on the last day of BIO-Europe Spring® Ma...